Literature DB >> 26305832

Approaches for monitoring of non virus-specific and virus-specific T-cell response in solid organ transplantation and their clinical applications.

Sandra A Calarota1, Judith H Aberle2, Elisabeth Puchhammer-Stöckl2, Fausto Baldanti3.   

Abstract

Opportunistic viral infections are still a major complication following solid organ transplantation. Immune monitoring may allow the identification of patients at risk of infection and, eventually, the modulation of immunosuppressive strategies. Immune monitoring can be performed using virus-specific and non virus-specific assays. This article describes and summarizes the pros and cons of the different technical approaches. Among the assays based on non virus-specific antigens, the enumeration of T-cell subsets, the quantification of cytokines and chemokines and the quantification of intracellular adenosine triphosphate following mitogen stimulation are described and their clinical applications to determine the risk for viral infection are discussed. In addition, current specific methods available for monitoring viral-specific T-cell responses are summarized, such as peptide-MHC multimer staining, intracellular cytokine staining, enzyme-linked immunospot and virus-specific IFN-γ ELISA assays, and their clinical applications to determine the individual risk for opportunistic viral infections with human cytomegalovirus, Epstein-Barr virus and polyoma BK virus are discussed. The standardization of the procedure, the choice of the antigen(s) and the criteria to define cut-off values for positive responses are needed for some of these approaches before their implementation in the clinic. Nevertheless, immune monitoring combined with virological monitoring in transplant recipients is increasingly regarded as a helpful tool to identify patients at risk of infection as well as to assess treatment efficacy.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Human cytomegalovirus; Immune monitoring approaches; Polyoma BK virus; Solid organ transplantation; T-cell immunity

Mesh:

Substances:

Year:  2015        PMID: 26305832     DOI: 10.1016/j.jcv.2015.07.299

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  9 in total

1.  Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.

Authors:  Angela Chiereghin; Luciano Potena; Laura Borgese; Dino Gibertoni; Diego Squarzoni; Gabriele Turello; Evangelia Petrisli; Giulia Piccirilli; Liliana Gabrielli; Francesco Grigioni; Tiziana Lazzarotto
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

2.  Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study.

Authors:  Angela Chiereghin; Giulia Piccirilli; Tamara Belotti; Arcangelo Prete; Clara Bertuzzi; Dino Gibertoni; Liliana Gabrielli; Gabriele Turello; Eva Caterina Borgatti; Francesco Barbato; Mariarosaria Sessa; Mario Arpinati; Francesca Bonifazi; Tiziana Lazzarotto
Journal:  Med Microbiol Immunol       Date:  2019-07-09       Impact factor: 3.402

3.  Positive conversion of interferon-γ release assay in patients with rheumatic diseases treated with biologics.

Authors:  Hye Won Kim; Oh Chan Kwon; Sang Hoon Han; Min-Chan Park
Journal:  Rheumatol Int       Date:  2020-01-09       Impact factor: 2.631

Review 4.  The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

Authors:  Brian J Ward; Stephane Pillet; Nathalie Charland; Sonia Trepanier; Julie Couillard; Nathalie Landry
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

5.  Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial.

Authors:  Aurora Paez-Vega; Sara Cantisan; José Manuel Vaquero; Elisa Vidal; Antonio Luque-Pineda; María Ángeles Lobo-Acosta; Ana Belén Pérez; Rodrigo Alonso-Moralejo; David Iturbe; Victor Monforte; Isabel Otero-Gonzalez; Amparo Pastor; Piedad Ussetti; Julian Torre-Cisneros
Journal:  BMJ Open       Date:  2019-08-15       Impact factor: 2.692

6.  Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation.

Authors:  Paolo Antonio Grossi; Nassim Kamar; Faouzi Saliba; Fausto Baldanti; Jose M Aguado; Jens Gottlieb; Bernhard Banas; Luciano Potena
Journal:  Transpl Int       Date:  2022-06-22       Impact factor: 3.842

Review 7.  BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection.

Authors:  Darlene Vigil; Nikifor K Konstantinov; Marc Barry; Antonia M Harford; Karen S Servilla; Young Ho Kim; Yijuan Sun; Kavitha Ganta; Antonios H Tzamaloukas
Journal:  World J Transplant       Date:  2016-09-24

8.  Usefulness of BK virus-specific interferon-γ enzyme-linked immunospot assay for predicting the outcome of BK virus infection in kidney transplant recipients.

Authors:  Hyunjoo Bae; Do Hyun Na; Ji-Yeun Chang; Ki Hyun Park; Ji Won Min; Eun Jeong Ko; Hyeyoung Lee; Chul Woo Yang; Byung Ha Chung; Eun-Jee Oh
Journal:  Korean J Intern Med       Date:  2020-04-03       Impact factor: 2.884

Review 9.  Virus-specific T cells in pediatric renal transplantation.

Authors:  Thurid Ahlenstiel-Grunow; Lars Pape
Journal:  Pediatr Nephrol       Date:  2020-03-27       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.